Mutation detail:
| Mutation site | 26450G>A |
| Virus | SARS-CoV-2 |
Mutation level  |
Nucleotide level |
| Gene/protein/region type | E |
| Gene ID | 43740570 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
Human |
| Variants | - |
| Viral reference sequence | MN908947.3 |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Envelope Protein |
| Uniprot protein ID | P0DTC4 |
| Protein length | 75 amino acids |
| Protein description | The SARS-CoV-2 envelope (E) protein is a small structural protein involved in many aspects of the viral life cycle. The E protein promotes the packaging and reproduction of the virus, and deletion of this protein weakens or even abolishes the virulence. |
Literature information:
| Pubmed ID | 33239633 |
| Clinical information | No |
| Disease | - |
| Published year | 2020 |
| Journal | Nature Communications |
| Title | No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2 |
| Author | Lucy van Dorp, Damien Richard, Cedric C S Tan, Liam P Shaw, Mislav Acman |
| Evidence | Supplementary Data1 |